ALKS - Alkermes plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Alkermes plc

Connaught House
1 Burlington Road
Dublin 4
Ireland
353 1 772 8000
http://www.alkermes.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees2,300

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard F. PopsChairman & CEO2.17M5.56M1962
Dr. Floyd E. BloomCo-Founder & Director89kN/A1937
Mr. James M. FratesSr. VP & CFO859.48kN/A1967
Mr. David Joseph GaffinSr. VP, Chief Legal Officer, Chief Compliance Officer & Sec.838.75k9.35k1972
Dr. Craig C. HopkinsonSr. VP of Medicines Devel. & Medical Affairs and Chief Medical Officer1.03MN/A1968
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Corporate Governance

Alkermes plc’s ISS Governance QualityScore as of April 1, 2019 is 3. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 5; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.